

BlueShield. FILGRASTIM Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

	Patient Inform	ation (required)	Prov	Provider Information (required)			
Date:				Provider Name:			
Patient Name:				Specialty:	NPI:	NPI:	
Date of Birth: Sex:			Female	Office Phone:	Office Fax:	Office Fax:	
Street Address:			Office Street Address:	:			
City:		State:	Zip:	City:	State:	Zip:	
Patient ID:		, ,]	Physician Signature:	-			
11		P	HYSICIAN	N COMPLETES			
		NOTE: Form m	ust be compl	eted in its entirety for pr	ocessing		
Please select m	nedication:	□Niv	astim-aafi)	m-aafi)			
**Check www.fepbl	lue.org/formulary to	confirm which medic	ation is part of	the patient's benefit			
Is this request for	r brand or generic	? □Brand □G	eneric				
1. What is the pa	atient's diagnosis?	•					
□Agranulocy	ytosis		☐Hematopoietic st	☐Hematopoietic stem cell transplantation			
□Aplastic anemia					Hematopoietic syndrome of acute radiation syndrome		
☐Hairy cell l		:		□Umbilical cord st	tem cell transplantation		
•	loid leukemia (AN			_	_		
	_	ction chemotherap	y or consolid	ation chemotherapy? \Box Y	es □No		
	lastic syndrome						
a. Is the p	patient neutropeni	c with recurrent of	r resistant inf	ections? \(\subseteq \text{Yes} \) \(\subseteq \text{No} \)			
☐Peripheral l	blood progenitor o	cell (PBPC) collec	tion				
	requested medicate antation? Yes	ion being used for No	autologous p	peripheral blood progenite	or cell (PBPC) mobiliz	ation and post	
□Neutropeni							
		e of the neutropen		lect the type or cause belo			
				c congenital neutropenia (nic neutropenia	(e.g., Kostmann's Synd	rome)	
□Cyto	omegalovirus-indu ciclovir-induced n			penia secondary to anti-re	ejection medications, po	ost-transplant	
	motherapy associa						
	Is the request for present the malignancy?		le neutropeni	ia following chemotherap	y for a solid or non-my	reloid reloid	
ii.	Is the patient cons	sidered to be at in	termediate or	high risk? □Yes □N	0		
□Нер	atitis C therapy as	sociated					
i. `	What is the patien	t's absolute neutro	ophil count (A	ANC) per cubic millimete	er (mm ³)?	mm^3	
□Othe	er (please specify):						
☐Other diagr	nosis (please speci	ify):					
			_	ulocyte colony-stimulation	•	Yes* □No	



FILGRASTIM PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. Please only fax the completed form once as duplicate submissions may delay processing times.

